Abstract: Provided herein is a microsuspension of an MDM2 inhibitor, comprising microparticles of the MDM2 inhibitor, e.g., a compound of Formula (I), a surfactant, and a tonicity agent. Also provided herein is a method of treating an MDM2-mediated disorder, disease, or condition with the microsuspension.

Abstract: A pharmaceutical composition and the use thereof. Specifically, disclosed is a pharmaceutical composition, comprising: a substance X, which is a compound as represented by formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof; and a substance Y, which is doxorubicin, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof. The pharmaceutical composition has a synergistic effect against ovarian cancer.

Abstract: Described herein are methods of treating a cancer, for example, a hematologic malignancy or a solid tumor, in a patient in need thereof, comprising administering to the patient a Bcl-2 inhibitor in combination with a second anti-cancer agent.

Abstract: The present invention relates to methods for treating patients with cancer, including patients with hematological malignancy, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.

Abstract: Methods for treating systemic lupus erythematosus using compounds or pharmaceutical compositions that modulate the activity of Bcl-2 family proteins are disclosed. In some methods, the patient to be treated is diagnosed with lupus nephritis. In some methods, the compound or pharmaceutical composition is administered to the patient in need thereof at a therapeutically effective dose sufficient to elicit one or more effects selected from: reduced excretion of protein in the urine of the patient, reduced serum anti-dsDNA autoantibody levels in the patient, reduced skin lesion severity in the patient, reduced lymphadenopathy severity in the patient, reduced glomerulonephritis severity in the patient, reduced vasculitis severity in the patient, reduced lymphocyte cell counts in a peripheral blood mononuclear cell (PMBC) panel taken from the patient, reduced lymphocyte cell counts in the spleen of the patient, and reduced lymphocyte infiltration of the kidneys of the patient.

Abstract: The present invention relates to a combination product comprising a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent, in particular a Bcl-2/Bcl-xL inhibitor of formula I-A and homoharringtonine or an active derivative thereof, in free or pharmaceutically acceptable salt or solvate form. The invention also relates to the use of the aforementioned combination for the preparation of a medicament for the prevention and/or treatment of cancer, in particular of hematological malignancies, and to a method for the prevention and/or treatment of cancer, in particular of hematological malignancies, using the aforementioned combination.

Abstract: The present invention relates to methods for treating patients with cancer, including patients with hematological malignancy, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.

Abstract: Described herein are methods of treating a cancer, for example, a hematologic malignancy or a solid tumor, in a patient in need thereof, comprising administering to the patient a Bcl-2 inhibitor in combination with a second anti-cancer agent.

Abstract: Described herein are methods of treating a hematologic malignancy in a patient in need thereof, comprising administering to the patient a Bcl-2 inhibitor in a step-wise dosing regimen.

Abstract: Provided herein is a combination product comprising a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent, in particular a Bcl-2/Bcl-xL inhibitor of formula (I-A) and homoharringtonine or an active derivative thereof, in free or pharmaceutically acceptable salt or solvate form. Provided herein is also the use of the aforementioned combination for the preparation of a medicament for the prevention and/or treatment of cancer, in particular of hematological malignancies, and to a method for the prevention and/or treatment of cancer, in particular of hematological malignancies, using the aforementioned combination.

Abstract: The invention discloses a novel pharmaceutical combination and a use thereof. The pharmaceutical combination comprises a compound of formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, and a compound of formula (II), a pharmaceutically acceptable salt thereof or a solvate thereof. The pharmaceutical combination can be used to treat cancer.

Abstract: Described herein are methods of treating a hematologic malignancy in a patient in need thereof, comprising administering to the patient a Bcl-2 inhibitor in a step-wise dosing regimen.

Abstract: The present invention relates to single therapy comprising an effective amount of a MDM2 inhibitor, as well as combination therapies comprising an effective amount of a modulator of the immune checkpoint molecule; and an effective amount of a MDM2 inhibitor, wherein the MDM2 inhibitor is represented by the following formula or a pharmaceutically acceptable salt thereof.

Abstract: Methods for treating immune diseases, specifically methods for the prevention and/or inhibition of autoimmune response or overactive immune response, comprising administering to the subject an effective amount of a compound of formula I, X or XI, or a pharmaceutically acceptable salt or solvate thereof. Methods for the prevention and/or inhibition of autoimmune disease, allergic disease or immune-mediated inflammatory disease, comprising administering to the subject an effective amount of a compound of formula I, X or XI, or a pharmaceutically acceptable salt or solvate thereof.

Abstract: Provided are biomarkers for predicting the efficacy of MDM2 inhibitor or Bcl-2/Bcl-xL dual inhibitors or Bcl-2 inhibitor or Bcl-xL inhibitor in treating cancer patients. Also provided are compositions, e.g., kits, for evaluating gene levels of the biomarkers and methods of using such gene levels to predict a cancer patient's response to the MDM2 inhibitors or Bcl-2/Bcl-xL dual inhibitors or Bcl-2 inhibitor or Bcl-xL inhibitor. Such information can be used in determining prognosis and treatment options for cancer patients.

Abstract: Provided are methods for treating hematologic malignancy, especially AML-MRC, MDS and/or MM. Specifically, provided are methods for treating AML-MRC and MDS with a compound of formula (I) or a pharmaceutically acceptable salt thereof, optionally in combination with at least one additional anti-cancer agent such as 5-azacitidine or cytarabine, and treating MM with a compound of formula (I) or a pharmaceutically acceptable salt thereof, optionally in combination with at least one additional anti-cancer agent such as pomalidomide, thalidomide, lenalidomide, and/or dexamethasone.

Abstract: Disclosed herein are combination therapies comprising an effective amount of a modulator of the immune checkpoint molecule; and an effective amount of a MDM2 inhibitor.

Abstract: The present invention pertains to the pharmaceutical field, and particularly relates to a pharmaceutical combination comprising a Bcl-2 inhibitor or a Bcl-2/Bcl-xL inhibitor and one or more anticancer reagents, and the use of the combination to treat a disease such as cancer, specifically acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or multiple myeloma (MM) resistant or insensitive to Bcl-2 inhibitors and/or carrying Bcl-2 mutation and/or TP53 mutation. The invention also relates to a pharmaceutical composition or kit comprising the combination.

Abstract: The invention discloses a novel pharmaceutical combination and a use thereof. The pharmaceutical combination comprises a compound of formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof; and a compound of formula (II), a pharmaceutically acceptable salt thereof or a solvate thereof. The pharmaceutical combination can be used to treat cancer.

Abstract: Provided herein are pharmaceutical compositions comprising an MDM2 inhibitor and one or more anti-cancer agents for preventing and/or treating diseases, such as cancer. Methods for preventing and/or treating diseases, such as cancer, comprising administering to the patient in need thereof with the pharmaceutical compositions are also provided.